870294-02-3

Basic information

• Product Name: (S)-ethyl 1-(1-((tert-butyldimethylsilyl)oxy)-3-methylbutan-2-yl)-7-fluoro-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate
• Synonyms: (S)-ethyl 1-(1-((tert-butyldimethylsilyl)oxy)-3-methylbutan-2-yl)-7-fluoro-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate;1-[(1S)-1-[[[(1,1-Dimethylethyl)dimethylsilyl]oxy]methyl]-2-methylpropyl]-7-fluoro-1,4-dihydro-6-iodo-4-oxo-3-quinolinecarboxylic acid ethyl ester
• CAS NO: 870294-02-3
• Molecular Formula: C₂₃H₃₃FINO₄Si
• Molecular Weight: 561.5007932
• EINECS: -0
• Mol File: 870294-02-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-ethyl 1-(1-((tert-butyldimethylsilyl)oxy)-3-methylbutan-2-yl)-7-fluoro-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-ethyl 1-(1-((tert-butyldimethylsilyl)oxy)-3-methylbutan-2-yl)-7-fluoro-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate(870294-02-3)
• EPA Substance Registry System: (S)-ethyl 1-(1-((tert-butyldimethylsilyl)oxy)-3-methylbutan-2-yl)-7-fluoro-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate(870294-02-3)

Safety Data

• Hazardous Substances Data: 870294-02-3(Hazardous Substances Data)

Usage

General Description

The chemical compound "(S)-ethyl 1-(1-((tert-butyldimethylsilyl)oxy)-3-methylbutan-2-yl)-7-fluoro-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate" is a complex organic molecule with a long name. It consists of a quinoline core structure with a carboxylate group and ethyl ester side chain. The molecule also contains a fluoro and iodo substituent, as well as a tert-butyldimethylsilyl protective group. Its stereochemistry is specified as (S)-ethyl, indicating the configuration of the ethyl group. (S)-ethyl 1-(1-((tert-butyldimethylsilyl)oxy)-3-methylbutan-2-yl)-7-fluoro-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate likely possesses diverse biological and chemical properties and may have potential applications in drug discovery, materials science, or other fields.

Upstream product

• 697762-60-0 7-fluoro-1-(1(S)-hydroxymethyl-2-methylprop-1-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 697762-39-3 ethyl 2-(2,4-difluoro-5-iodobenzoyl)-3-(dimethylamino)acrylate 
• 2026-48-4 (S)-valinol 
• 1583-58-0 2,4-difluoro-benzoic acid 
• 161531-51-7 2,4-difluoro-5-iodobenzoic acid 
• 72-18-4 L-valine 
• 697762-59-7 C₁₇H₂₀F₂INO₄ 

Downstream Products

• 1261283-94-6 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-((S)-1-hydroxymethyl-2-methylprop-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid dicyclohexylamine salt 
• 1261283-95-7 1(S)-[1-(tert-butyldimethylsilanyloxymethyl)-2-methylprop-1-yl]-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261283-97-9 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-[2-methyl-1-(tetrahydropyran-2-yloxymethyl)prop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261283-99-1 1-(S)-[1-(tert-butyldimethylsilanyloxymethyl)-2-methylprop-1-yl]-6-(3-chloro-2-fluorobenzyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261284-01-8 6-(3-chloro-2-fluorobenzyl)-7-methoxy-1-[1-(S)-2-methyl-1-(tetrahydropyran-2-yloxymethyl)prop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 697761-98-1 elvitegravir 
• 869893-92-5 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-((S)-1-hydroxymethyl-2-methylprop-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 697762-66-6 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-[1-(S)-tert-butyldimethylsilyloxymethyl-2-methylprop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 

Relevant articles and documents

AN IMPROVED PROCESS FOR THE PREPARATION OF ELVITEGRAVIR

The present invention relates to improved process for the preparation of elvitegravir (12), wherein the compound of formula (6) is protected with suitable protecting agents and further reacted with formula (9) in the presence of tetrakis(triphenylphosphin

Novel HIV-1 integrase inhibitors derived from quinolone antibiotics

The viral enzyme integrase is essential for the replication of human immunodeficiency virus type 1 (HIV-1) and represents a remaining target for antiretroviral drugs. Here, we describe the modification of a quinolone antibiotic to produce the novel integr